Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Aquestive Therapeutics
AQST
Aquestive Therapeutics
Reimbursement Barriers And Competition Will Curtail Adoption Yet Potential Appears
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$4.75
16.2% undervalued
intrinsic discount
16 Aug
US$3.98
Loading
1Y
-10.8%
7D
-3.2%
Author's Valuation
US$4.8
16.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$4.8
16.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-73m
77m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$54.1m
Earnings US$12.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
37.55%
Pharma revenue growth rate
0.56%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$12.57m
Earnings '28
x
60.27x
PE Ratio '28
=
US$757.40m
Market Cap '28
US$757.40m
Market Cap '28
/
130.98m
No. shares '28
=
US$5.78
Share Price '28
US$5.78
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$4.75
Fair Value '25
